Drug results: 1

ensitrelvir Ensitrelvir is an orally active 3C-like protease inhibitor and it was approved for emergency use in Japan in November 2022. Ensitrelvir has reached Phase III clinical trials and is being evaluated for its efficacy and safety in patients with mild-to-moderate COVID-19.

DrugCentral Search Overview